Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASCO 2025 Skin Cancer Highlights
Featuring presentations & discussions on selected skin cancer abstracts from the 2025 American Society of Clinical Oncology (ASCO) annual meeting.
Chair: Meredith McKean | Moderators: Dirk Schadendorf, Isabella Glitza de Oliva
Session 1: Refining BRAF-targeting approaches in melanoma
DREAMseq: A phase III trial of treatment sequences in BRAFV600-mutant (m) metastatic melanoma (MM)—Final clinical results
Michael Atkins Georgetown Lombardi Comprehensive Cancer Center, Washington DC, United States
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 (NCT04511013)
Zeynep Eroglu H. Lee Moffitt Cancer Center and Research Institute , Tampa, FL, United States
Panel discussion
Session 2: Novel nivolumab combination approaches in advanced melanoma
A phase II study of the interleukin-6 (IL-6) receptor blocking antibody sarilumab (Sari) in combination with ipilimumab (Ipi), nivolumab (Nivo) and relatlimab (Rela) in patients with unresectable stage III or stage IV melanoma
Janice Mehnert Perlmutter Cancer Center, New York, NY, United States
Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An updated indirect treatment comparison (ITC) with 4-year follow-up data
Dirk Schadendorf University Hospital Essen, Essen, Germany
Panel discussion
Session 3: Enhancing immunotherapy strategies in advanced melanoma and CSCC
Phase 3 trial of adjuvant cemiplimab (cemi) versus placebo (pbo) for high-risk cutaneous squamous cell carcinoma (CSCC)
Danny Rischin Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
Neoadjuvant camrelizumab plus apatinib and temozolomide for resectable stage II/III acral melanoma: The CAP 03-NEO trial
Lili Mao Peking University Cancer Hospital and Insitute, Bejing, China
Comparison of 1 year versus minimum 2 years of anti-PD1-based immunotherapy as first-line treatment for metastatic melanoma: Results of the DANTE phase III trial
Sarah Danson University of Sheffield NHS Foundation Trust , Sheffield, United Kingdom
Panel discussion
Session 4: Innovative and investigational therapies in melanoma
Clinical outcomes of the DIET study: A randomized controlled phase 2 trial of a high fiber diet intervention (HFDI) in patients with melanoma receiving immune checkpoint blockade (ICB)
Jennifer McQuade The University of Texas MD Anderson Cancer Center, Houston, TX, United States
OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy with regulatable membrane-bound IL15 (mbIL15) in patients (pts) with immune checkpoint inhibitor (ICI)–resistant advanced melanoma: Phase 1 results of the Agni-01 multicenter study
Allison Betof Warner Stanford Medicine, Stanford, CA, United States
Panel discussion
